Peng Zhang

Peng Zhang

Auto-generated profile, based on publicly available information

Peng Zhang

Department of Biostatistics and Programming, Brightech International, Somerset, NJ

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2015 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PZPeng Zhang
Peng Zhang
JYJingying Ye
Jingying Ye
CPChuxiong Pan
Chuxiong Pan
NSNian Sun
Nian Sun
DKDan Kang
Dan Kang

1 January 2020 in Open Access Journal of Clinical Trials
Verified
Journal Article
Open access
PDF file
WSWeichung J Shih
Weichung J Shih
XSXin Shen
Xin Shen
PZPeng Zhang
Peng Zhang
TXTai Xie
Tai Xie
Introduction: The first clinical trial on remdesivir for treatment of severe COVID-19 conducted in China was terminated prematurely due to limited patient enrollment, which rendered the findings inconclusive. We re-analyzed the efficacy with a statistically more powerful and clinically meaningful method based on published data using the 6-point ordinal scale of patient's disease severity. Methods: We defined response as patient's point reached, either 2 (hospitalized, no requirement for supplementary oxygen therapy) or 1 (discharged or met discharge criterion), and then analyzed with logistic regression with baseline score, day of assessment, treatment group, baseline by treatment interaction, and day by treatment interaction as covariates. The binary endpoint was supported by the recent FDA's guidance on COVID-19. Results: Eighty-two percent (82%) of the patients were in the disease severity point=3 (hospitalized, required supplemental oxygen (but not NIV/HFNC)) - the moderately severe category. The response rate was 85% for remdesivir-treated patients with baseline disease point=3 versus 70% response rate for likewise placebo-treated patients on Day 28 (OR=2.38, P=0.0012). On Day 14, the response rate for these patients was 43% for remdesivir versus 33% for placebo (OR=1.53, P=0.0022). For patients with baseline disease point=4 (critically severe category), no similar comparisons were statistically significant. Conclusion and Discussion: The Chinese trial was not really under-powered as previously perceived or portrayed by many opinions. This result supports the preliminary findings of ACTT that remdesivir is effective for patients who were not critically severe. This result also suggests that remdesivir should be given to hospitalized COVID-19 patients as soon as possible. There is no race difference in the treatment effect.

8 March 2021 in Statistics in Biopharmaceutical Research
Verified
Journal Article
Open access
TXTai Xie
Tai Xie
PZPeng Zhang
Peng Zhang
WSWeichung Joe Shih
Weichung Joe Shih
YTYue Tu
Yue Tu
KLK. K. Gordon Lan
K. K. Gordon Lan
In late 2019, the US FDA updated a new Guidance for Industry on Adaptive Designs for Clinical Trials of Drugs and Biologics. The guideline encourages developing and implementing innovative trial designs for future clinical trials. Group sequential, sample size re-estimation, and adaptive group sequential procedures have been very useful for improving the efficiency of conducting trials for decades. However, they face some challenges in operational aspects which limited their potentials. In this paper we introduce a procedure that addresses these issues. Our proposed procedure has the capability of providing anytime accessibility of the whole up-to-date data history. The procedure is largely built on the proven adaptive group sequential design theories and combined with advanced eClinical technologies in trial management to elevate the trial design and monitoring to a more dynamic level. The construct of a new trial monitoring screen is illustrated with real trial examples. The advantages of anytime accessibility of data and the monitoring a trial with the whole data history and trend are delineated. Data monitoring committees, sponsors and regulatory authorities are important stakeholders in the discussion of how future clinical trials should be monitored with respect to timing and frequency.